Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Sisram Medical Ltd. ( (HK:1696) ).
Sisram Medical Ltd has announced significant changes in its leadership structure, effective from January 1, 2026. Mr. Yi Liu will transition from Chairman to a non-executive Director, while Mr. Lior Moshe Dayan will become the new Chairman. Mr. Eyal Ben David will take over as Chief Executive Officer, with Mr. Jiahong Li appointed as Co-Chief Executive Officer. These changes are part of a strategic realignment within the company, aiming to enhance its operational efficiency and strengthen its market position.
The most recent analyst rating on (HK:1696) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
More about Sisram Medical Ltd.
Sisram Medical Ltd, incorporated in Israel, operates in the medical industry, focusing on providing advanced medical solutions. It is part of the Fosun Pharma Group, which is known for its pharmaceutical and healthcare services.
Average Trading Volume: 722,725
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.97B
For a thorough assessment of 1696 stock, go to TipRanks’ Stock Analysis page.